Literature DB >> 3514472

[Respiratory tract infections--clinical results with ofloxacin].

P M Shah, H Knothe.   

Abstract

In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b. i. d. orally. 36 had acute bronchitis and pneumonia was diagnosed in 44. The average duration of therapy was nine days for bronchitis and 12 days for pneumonia. In the sputum of bronchitis patients, Haemophilus influenzae (n = 25), Streptococcus pneumoniae (n = 18), Branhamella catarrhalis (n = 2) and Pasteurella multocida (n = 1) were isolated. 17 H. influenzae and 12 S. pneumoniae were eliminated. All 20 S. pneumoniae strains isolated from patients with pneumonia were eliminated. A cure or improvement of clinical symptoms was seen in 32 of 36 cases of bronchitis and in 33 of 44 cases of pneumonia treated with ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514472     DOI: 10.1007/bf01645206

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  3 in total

1.  Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.

Authors:  G Ruckdeschel; W Ehret; A Ahl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

2.  Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.

Authors:  G Seibert; M Limbert; N Klesel
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

3.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

  3 in total
  5 in total

1.  [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].

Authors:  M Verho; E E Dagrosa; V Malerczyk
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin.

Authors:  T Fritzen; E Marx; J Uy
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 3.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae.

Authors:  P M Shah; V Schäfer; T Hubener; C Metz; W Stille
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Diffusion of ofloxacin into human lung tissue.

Authors:  L Couraud; J B Fourtillan; M C Saux; A Bryskier; M Vincent du Laurier
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.